Fundraising Fox
Boostertx
Founded 2020 · 11 employees on LinkedIn · 3 known investors
Find your way into Boostertx
Sign up to see every warm intro you have to Boostertx
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Boostertx team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools. The company is building a multi-disease pipeline initially focused on neurodegenerative diseases.
Founders & leadership
Boostertx was founded in 2020 by Diogo R. Feleciano and Darci J. Trader.
DR
Diogo R. FelecianoCo-Founder & CSODiogo Feleciano co-founded Booster Therapeutics in 2020 and serves as Chief Scientific Officer. He has over a decade of experience in life sciences spanning academic research, venture capital, and biotech, with expertise in R&D, company building, and aging, neurology, and ocular biology.
DJ
Darci J. TraderScientific Co-Founder / Advisor
JR
João RibasInterim-CBOJoão Ribas is a biotech operator and venture investor who has held board positions and operational roles across multiple therapeutics companies including Asgard Therapeutics, Booster Therapeutics, Orbis Medicines, and Tribune Therapeutics, and currently serves as interim executive at Booster Therapeutics while leading venture creation efforts at BiOrigin.
Investors · 3
Frequently asked questions
- What does Boostertx do?
- Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools. The company is building a multi-disease pipeline initially focused on neurodegenerative diseases.
- Who founded Boostertx?
- Boostertx was founded by Diogo R. Feleciano, Darci J. Trader in 2020.
- Who are Boostertx's investors?
- Boostertx's investors include Apollo Health Ventures, Novo Holdings, Korify Capital.